share_log

EF Hutton Assumes Jasper Therapeutics at Buy, Announces Price Target of $6.85

Benzinga ·  May 25, 2023 07:06

EF Hutton analyst Michael King assumes Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces Price Target of $6.85.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment